Share on StockTwits

Investment analysts at Leerink Swann started coverage on shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $25.00 price target on the stock. Leerink Swann’s price target suggests a potential upside of 38.27% from the company’s current price.

A number of other analysts have also recently weighed in on TKMR. Analysts at Maxim Group reiterated a “hold” rating on shares of Tekmira Pharmaceuticals in a research note on Friday, August 8th. They now have a $23.00 price target on the stock. Separately, analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $26.30.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 19.2826 on Monday. Tekmira Pharmaceuticals has a 1-year low of $5.08 and a 1-year high of $31.48. The stock has a 50-day moving average of $12.84 and a 200-day moving average of $15.94.

Tekmira Pharmaceuticals (NASDAQ:TKMR) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.26) by $0.02. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $3.72 million. On average, analysts predict that Tekmira Pharmaceuticals will post $-1.59 earnings per share for the current fiscal year.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.